











The Study of Pharmaceutical Policy from




The international comparison study was examined. The price controls on prescription drugs
have been prominent in Europe. But, strict drug price controls were not sufficient to restrain
growth of drug utilization and total pharmaceutical spending. In the United States, the debate
has centered on drug prices, because high prices can impede people's access to prescription
drugs. But, management methods derived from managed care settings to improve the cost-
effectiveness of prescribing are important measures to obtain the best values for money. Phar-
maceutical policy should be considered of healthcare as a totality.
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1988年に開業医を対象に導入されたPACT (Prescribing Analysis and Cost System :処































































































































































































































診療保険)などのIndemnity、マネジドケアにおけるHMO (Health Maintenance Organiza-
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総じて欧米諸国の政策は、 「健全な国際市場の形成」、 「競争の歪みの忌避」、 「国民の薬剤へ
のアクセス保障」を目指している。日本においては、医薬分業がまだ確立していない、医薬
6) Report to the President, Prescription Drug Coverage, Spending, Utilization, and Prices, the Department of
Health & Human Services, April 2000
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